Azithromycin for Child Survival in Niger II

Several randomized controlled trials have demonstrated that azithromycin mass drug administration (MDA) reduces child mortality, but increases antimicrobial resistance (AMR). The World Health Organization (WHO) guidelines for this intervention specify that implementation must be accompanied by continued monitoring of mortality and AMR. Niger is expanding the azithromycin MDA program nationwide. To establish monitoring of mortality and AMR as part of this program as well as to leverage the infrastructure to evaluate other child health interventions, AVENIR II is designed as an adaptive platform trial with monitoring and re-randomization every 2 years.

NCT Number	NCT06358872
Lead Sponsor	University of California, San Francisco Collaborators: Centre de recherche et interventions en santé publique (CRISP), Ministère de la Santé Publique du Niger, Le Programme National de Santé Oculaire, Centre de Recherche Médicale et Sanitaire, Bill and Melinda Gates Foundation
Conditions	Mortality, Antimicrobial Resistance
Enrollment	3,300,000 participants
Start Date	2024-04-29
Primary Completion	2028-04-29 (estimated)
Study Completion	2028-04-29 (estimated)
Updated on ClinicalTrials.gov	2026-07-14